Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Imaging Axl expression in pancreatic and prostate cancer xenografts.

Nimmagadda S, Pullambhatla M, Lisok A, Hu C, Maitra A, Pomper MG.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):635-40. doi: 10.1016/j.bbrc.2013.12.014.


Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.

Mishra A, Wang J, Shiozawa Y, McGee S, Kim J, Jung Y, Joseph J, Berry JE, Havens A, Pienta KJ, Taichman RS.

Mol Cancer Res. 2012 Jun;10(6):703-12. doi: 10.1158/1541-7786.MCR-11-0569.


Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.

Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B.

Oncogene. 2014 Nov 20;33(47):5405-14. doi: 10.1038/onc.2013.487.


Axl-targeted cancer imaging with humanized antibody h173.

Li D, Liu S, Liu R, Park R, Yu H, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS.

Mol Imaging Biol. 2014 Aug;16(4):511-8. doi: 10.1007/s11307-013-0714-z.


Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA.

Cancer Res. 2015 Sep 15;75(18):3699-705. doi: 10.1158/0008-5472.CAN-14-2887-T.


Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-D-glucose in human pancreatic carcinoma xenografts and in inflammation models.

Hellwig D, Menges M, Schneider G, Moellers MO, Romeike BF, Menger MD, Kirsch CM, Samnick S.

Nucl Med Biol. 2005 Feb;32(2):137-45.


Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor.

Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC.

J Cell Physiol. 2005 Jul;204(1):36-44.


Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.

Gustafsson A, Boström AK, Ljungberg B, Axelson H, Dahlbäck B.

PLoS One. 2009 Oct 30;4(10):e7575. doi: 10.1371/journal.pone.0007575.


Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.

Liu S, Li D, Guo J, Canale N, Li X, Liu R, Krasnoperov V, Gill PS, Conti PS, Shan H, Li Z.

Mol Pharm. 2014 Nov 3;11(11):3974-9. doi: 10.1021/mp500307t.


177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.

Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE.

J Nucl Med. 2009 Dec;50(12):2017-24. doi: 10.2967/jnumed.109.064444.


Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, Graham DK.

Oncogene. 2013 Jul 18;32(29):3420-31. doi: 10.1038/onc.2012.355.


Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.

Fozing T, Scheuer C, Samnick S.

Eur J Med Chem. 2010 Sep;45(9):3780-6. doi: 10.1016/j.ejmech.2010.05.027.


Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.

Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, Ferris C, Tekabe Y, Khaw BA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):824-39. doi: 10.1007/s00259-011-2050-3.


Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.

Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R, Melillo RM.

Cancer Res. 2011 Mar 1;71(5):1792-804. doi: 10.1158/0008-5472.CAN-10-2186.


The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.

Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, Bhasin M, Libermann TA, Zerbini LF.

Oncogene. 2013 Feb 7;32(6):689-98. doi: 10.1038/onc.2012.89.


Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.

Ishikawa M, Sonobe M, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Date H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S467-76. doi: 10.1245/s10434-012-2795-3.


Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.

Nimmagadda S, Pullambhatla M, Pomper MG.

J Nucl Med. 2009 Jul;50(7):1124-30. doi: 10.2967/jnumed.108.061325.


PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.

Elsässer-Beile U, Reischl G, Wiehr S, Bühler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla HJ, Pichler BJ.

J Nucl Med. 2009 Apr;50(4):606-11. doi: 10.2967/jnumed.108.058487. Erratum in: J Nucl Med. 2009 Jun;50(6):958.


Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.

Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, Torka R.

Cancer Biol Ther. 2014;15(11):1571-82. doi: 10.4161/15384047.2014.956634.


Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis.

He L, Zhang J, Jiang L, Jin C, Zhao Y, Yang G, Jia L.

Mol Carcinog. 2010 Oct;49(10):882-91. doi: 10.1002/mc.20664.

Items per page

Supplemental Content

Support Center